HomeProductsBioactive CompoundsGPCR & G Protein TargetsGPCRFasiglifam
Chemical structure of CAS 1000413-72-8

Fasiglifam

CAS No.1000413-72-8
MDL No.MFCD18251445
MFC29H32O7S
MW524.60
InChI KeyBZCALJIHZVNMGJ-HSZRJFAPSA-N

Pricing & Availability

Pack SizePurityPriceAvailabilityAction
- -On RequestOn Request
Custom synthesis and bulk supply options are available upon request.

Product Information

Fasiglifam is a biphenyl compound.

CAS No.1000413-72-8
Product NameFasiglifam

Biological Targets

FFAR1

Associated Conditions

diabetes mellitus·type 2 diabetes mellitus
* The information provided here is compiled from public sources and is for reference only.

Related Articles

Studies related to this compound and its mechanism of action

Comparative hepatic transcriptome analyses revealed possible pathogenic mechanisms of fasiglifam (TAK-875)-induced acute liver injury in mice.

Chemico-biological interactions • Vol. 296 • 2018
PMID: 30243991DOI: 10.1016/j.cbi.2018.09.011

Fasiglifam (TAK-875): Mechanistic Investigation and Retrospective Identification of Hazards for Drug Induced Liver Injury.

Toxicological sciences : an official journal of the Society of Toxicology • Vol. 163, Issue 2 • 2018
PMID: 28206647DOI: 10.1093/toxsci/kfx040

Fasiglifam (TAK-875) Alters Bile Acid Homeostasis in Rats and Dogs: A Potential Cause of Drug Induced Liver Injury.

Toxicological sciences : an official journal of the Society of Toxicology • Vol. 157, Issue 1 • 2017
PMID: 28108665PMC: PMC5414857DOI: 10.1093/toxsci/kfx018

Efficacy and safety of fasiglifam (TAK-875), a G protein-coupled receptor 40 agonist, in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise: a randomized, double-blind, placebo-controlled, phase III trial.

Diabetes, obesity & metabolism • Vol. 17, Issue 7 • 2015
PMID: 25787200PMC: PMC4676912DOI: 10.1111/dom.12467

Documentation

Similar Products